Hepatitis C: Down but not out

Annals of Internal Medicine

Volumn 166, Issue 9, 2017, Pages 675-676

  Hoofnagle, Jay H ^a   Sherker, Averell H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DASABUVIR; GRAZOPREVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERFERON; PARITAPREVIR; SIMEPREVIR; SOFOSBUVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DECOMPENSATED LIVER CIRRHOSIS; DRUG COST; EDITORIAL; END STAGE LIVER DISEASE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW (TOPIC); VIREMIA; VIRUS REACTIVATION; HEPACIVIRUS;

HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 85020757144     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M17-0567     Document Type: Editorial

References (10)

1. Falade-Nwulia O., Suarez-Cuervo C, Nelson D.R., Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection. A systematic review. Ann Intern Med. 2017; 166:637-48. doi:10.7326/M16-2575
2. Smith BD, Morgan RL, Beckett G.A., Falck-Ytter Y, Holtzman D, Teo C.G., et al; Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012; 61:1-32. [PMID: 22895429]
3. Sofosbuvir/velpatasvir (Epclusa) for hepatitis C. Med Lett Drugs Ther. 2016; 58:107-8. [PMID: 27508349]
4. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al; ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015; 373:2599-607. [PMID: 26571066] doi:10.1056/NEJMoa1512610
5. Zeuzem S, Ghalib R, Reddy K.R., Pockros PJ, Ben Ari Z, Zhao Y, et al Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163:1-13. [PMID: 25909356] doi:10.7326/M15-0785
6. Collins JM, Raphael KL, Terry C, Cartwright E.J., Pillai A., Anania FA, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015; 61:1304-6. [PMID: 26082511] doi:10.1093/cid/civ474
7. Dyson JK, Hutchinson J, Harrison L., Rotimi O, Tiniakos D, Foster G.R., et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016; 64:234-8. [PMID: 26325535] doi: 10.1016/j.jhep.2015.07.041
8. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. Silver Spring, MD: U.S. Food and Drug Administration; 2016. Accessed at www.fda.gov/Drugs/DrugSafety/ucm522932.htm on 3 March 2017.
9. Innes H, McDonald S, Hayes P., Dillon JF, Allen S, Goldberg D, et al Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol. 2017; 66: 19-27. [PMID: 27545496] doi:10.1016/j.jhep.2016.08.004
10. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution [Editorial]. J Hepatol. 2016; 65:663-5. [PMID: 27417216] doi:10.1016/j.jhep.2016.07.004